NCT07011524

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of CM512 Injection in Subjects With Moderate-to-severe Asthma.

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
BIOLOGICAL	CM512 injection	subcutaneous injection
DRUG	Placebo	subcutaneous injection

Timeline

• Start date: 2025-08-19
• Primary completion: 2027-07-21
• Completion: 2027-07-21
• First posted: 2025-06-08
• Last updated: 2025-08-28

Locations

1 site across 1 country: China